Want to see CNSP full AI Analyst Report?
Top Page
CNS Pharmaceuticals
(NASDAQ:CNSP)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.00
▼(-9.42% Downside)
Action:Reiterated
Date:10/02/26
The score is primarily held down by weak financial performance—no revenue base, ongoing losses, and consistent cash burn—despite low leverage and improved equity. Technicals are mixed with negative MACD and price below shorter-term averages, while valuation is constrained by a negative P/E and no dividend. Corporate events provide a partial offset via financing and strategic reset, but do not eliminate execution and funding risks.
Positive Factors
Low leverage and improved equity
A debt-free balance sheet reduces fixed financial obligations and preserves flexibility while the company funds clinical development. The substantial improvement in equity after recapitalization provides a stronger foundation than prior periods, although continued cash burn remains important.
Negative Factors
Pre-revenue business model
Without recurring product or service revenue, CNS Pharmaceuticals cannot currently fund operations through customer demand or commercial cash inflows. Its ability to advance the pipeline therefore remains dependent on financing access until a candidate or diagnostic generates meaningful income.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and improved equity
A debt-free balance sheet reduces fixed financial obligations and preserves flexibility while the company funds clinical development. The substantial improvement in equity after recapitalization provides a stronger foundation than prior periods, although continued cash burn remains important.
Read all positive factors
CNS Pharmaceuticals (CNSP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.58M
Dividend YieldN/A
Average Volume (3M)4.27K
Price to Earnings (P/E)―
Beta (1Y)3.51
Revenue GrowthN/A
EPS Growth88.43%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-23.59
Shares Outstanding1,461,449
10 Day Avg. Volume3,650
30 Day Avg. Volume4,266
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap1.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit38.14K
Enterprise Value/Ebitda-0.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$40.76M
CNS Pharmaceuticals Business Overview & Revenue Model
Company Description
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthr...
How the Company Makes Money
CNS Pharmaceuticals does not have a disclosed, established commercial product revenue stream; as a clinical-stage company, its operations have primarily been funded through financing activities rather than recurring sales. Accordingly, detailed, r...
CNS Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
45
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 333.00 | 0.00 | -3.31K | -4.13K | -11.76K | -13.07K |
| EBITDA | -16.67M | -15.83M | -14.84M | -18.83M | -15.26M | -14.47M |
| Net Income | -16.70M | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
Balance Sheet | ||||||
| Total Assets | 21.94M | 8.62M | 8.70M | 1.70M | 13.05M | 8.76M |
| Cash, Cash Equivalents and Short-Term Investments | 19.98M | 7.20M | 6.46M | 548.72K | 10.06M | 5.00M |
| Total Debt | 0.00 | 328.57K | 326.07K | 300.81K | 409.97K | 387.79K |
| Total Liabilities | 3.74M | 4.10M | 2.52M | 6.13M | 4.92M | 2.14M |
| Stockholders Equity | 18.20M | 4.52M | 6.18M | -4.43M | 8.13M | 6.62M |
Cash Flow | ||||||
| Free Cash Flow | -13.44M | -13.83M | -17.12M | -14.14M | -10.56M | -13.54M |
| Operating Cash Flow | -13.41M | -13.81M | -17.11M | -14.14M | -10.56M | -13.54M |
| Investing Cash Flow | -28.18K | -18.18K | -4.19K | -3.90K | -4.42K | -5.75K |
| Financing Cash Flow | 21.30M | 14.57M | 23.03M | 4.64M | 15.61M | 4.51M |
CNS Pharmaceuticals Technical Analysis
Negative
5.52
Price Trends
5.48
Negative
5.21
Negative
4.64
Positive
Market Momentum
-0.05
Negative
45.19
Neutral
65.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSP, the sentiment is Negative. The current price of 5.52 is above the 20-day moving average (MA) of 5.25, above the 50-day MA of 5.48, and above the 200-day MA of 4.64, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.19 is Neutral, neither overbought nor oversold. The STOCH value of 65.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNSP.
CNS Pharmaceuticals Risk Analysis
CNS Pharmaceuticals disclosed 36 risk factors in its most recent earnings report. CNS Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CNS Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $3.43M | -0.04 | -134.03% | ― | ― | 93.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $7.58M | -0.22 | -204.25% | ― | ― | 88.43% | |
41 Neutral | $394.34K | >-0.01 | -42.42% | ― | ― | 97.97% | |
| ― | $2.02M | -0.13 | -144.23% | ― | ― | 86.26% | |
43 Neutral | $7.47M | -0.39 | -134.73% | ― | -60.74% | 66.05% |
* Healthcare Sector Average
CNSP
CNS Pharmaceuticals
5.19
-4.35
-45.60%
BDRX
Biodexa Pharmaceuticals
0.38
-41.62
-99.09%
OGEN
Oragenics
0.45
-0.94
-67.84%
INM
InMed Pharmaceuticals
1.36
-0.84
-38.18%
GRI
GRI Bio
1.57
-51.91
-97.06%
CNS Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
CNS Pharmaceuticals Shareholders Approve Key Governance Measures
Positive
Oct 2, 2026
On September 30, 2026, CNS Pharmaceuticals held its Annual Meeting of Stockholders, with 45.72% of the 1,461,449 outstanding common shares represented, establishing a quorum for voting. Shareholders elected six directors to serve until the 2027 an...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment
Positive
Jul 2, 2026
On July 2, 2026, CNS Pharmaceuticals posted a June 2026 investor presentation outlining a disciplined strategic reset anchored in oncology and neurology assets. Following a comprehensive review, management concluded that its historic focus on glio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.